SYNAPTOGENIX INC (SNPX)

Company Profile

Synaptogenix, Inc. is a biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer’s disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson’s Disease, Traumatic Brain Injury, and Stroke. The company is headquartered in New York City, New York and currently employs 5 full-time employees. The company went IPO on 2020-12-07. The firm is principally focused on developing therapeutics for patients with neurodegenerative diseases and developmental disorders. The firm is focused on developing a product platform based on a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimer's disease (AD). Bryostatin-1 is a Protein Kinase C Epsilon (PKC e), a and e activator that was originally developed as a potential anticancer drug. The firm is evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease.

Company Info

SYNAPTOGENIX INC

1185 Avenue Of The Americas, 3Rd Floor

New York City NEW YORK

P: 19732420005

CEO: Alan J. Tuchman

Employees: 5

Website: https://www.synaptogen.com/